This year marks five years since COVID-19 was declared a pandemic, a significant milestone in the history of vaccinology. The pandemic’s immense global impact underscored the necessity of vaccines, spotlighted manufacturing efficacy, shifted public perspectives on immunization, and propelled advancements in vaccine technology that continue to drive scientific breakthroughs.
As we transition into another promising year for immunology and vaccine development research, it’s essential to reflect on the state of the industry and look to identify key opportunities ahead.
Exploring Industry Innovations and Expanding Our Vaccine Portfolio
The past year witnessed many notable developments across the vaccine industry and within our network. Atlantic Health Partners now serves over 45,000 clinicians across all 50 states and Puerto Rico, extending partnerships to independent pharmacies and long-term elder care facilities. Additionally, we expanded our services, giving members access to the latest COVID-19, respiratory syncytial virus (RSV), cholera, rabies, and pneumococcal vaccines.
Beyond our network, vaccine innovation continued to evolve. The Advisory Committee on Immunization Practices (ACIP) updated recommendations for RSV and pneumococcal vaccines to enhance protection for older adults and address disparities in disease burden. This year also ushered in a new phase of vaccine innovation, with clinical trials and studies paving the way for breakthroughs using mRNA, T-cells, and compound vaccines.
As we forge ahead into the post-COVID-19 era, clinicians can play a transformative role in improving pediatric and adult vaccine coverage rates. By distributing evidence-backed vaccination information, addressing vaccine hesitancy, and proactively engaging with patients to discuss routine immunization benefits, healthcare providers can combat misinformation and boost immunization rates––bringing public health closer to pre-pandemic levels.
Strengthening Vaccine Strategies in 2025 and Beyond
The new year presents both new opportunities and potential challenges for vaccine development and purchasing. With scientific advancements accelerating, numerous vaccines are entering the pipeline, targeting key pathogens, including HIV, malaria, tuberculosis, RSV, and more. Breakthrough mRNA technology, which enabled rapid COVID-19 vaccine development, continues to show promise in preventing and treating infectious diseases such as avian bird flu, norovirus, and influenza.
As the nation’s leading vaccine buying group, Atlantic Health Partners is prepared to navigate these developments and help healthcare providers access the latest vaccines at favorable pricing.
While monumental for public health, industry growth and innovation can also complicate product selection for practices. Our client support team is committed to staying ahead of industry trends and developments, providing members with the right resources and insights needed to make informed purchasing decisions—whether through direct suppliers or distributors—and understanding how those choices impact pricing. Our longstanding relationships with leading manufacturers and distributors like McKesson enable us to deliver timely updates and ensure members are equipped to optimize their vaccine programs.
Now more than ever, healthcare providers play a vital role in safeguarding communities. As the vaccine landscape continues to evolve with new capabilities, products, and regulations, vaccines will remain a cornerstone of public health and well-being. In 2025 and beyond, Atlantic Health Partners is dedicated to making this vision a reality. By helping healthcare practices align their vaccine preferences with favorable pricing, our team empowers members to expand access to routine vaccinations and enhance immunization programs for patients of all ages.